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Objective: To determine the association between three ﬁbulin-3 peptides and the incidence of radio-
graphic and clinical knee osteoarthritis (OA).
Design: Women between 50 and 60 years, with a BMI 27 kg/m2, free of knee OA, were recruited. Using
binary logistic regression, the association between baseline concentration of serum ﬁbulin (Fib)3-1, Fib3-
2 and Fib3-3 and incidence of clinical and radiographic knee OA after 30 months of follow-up was
evaluated.
Results: Baseline and follow-up measurements were available for 241 women with a mean age of
55.9 ± 3.2 years and mean BMI of 31.7 ± 3.6 kg/m2. None of the concentrations of the three Fib3 epitopes
were associated with the incidence of medial or lateral joint space narrowing (JSN) 1.0 mm or the
incidence of Kellgren & Lawrence (K&L) grade 2 after 30 months. All three Fib3 epitopes were asso-
ciated with the incidence of the clinical and radiographic ACR-criteria and Fib3-1 and Fib3-3 also with
chronic pain at follow-up. When adjusted for the other Fib3 peptide concentrations, only Fib3-1 was
signiﬁcantly associated to the incidence of the American College of Rheumatology (ACR)-criteria (OR 3.2
[1.2e8.7]) and chronic pain at follow-up (OR 3.0 [1.2e7.7]).
Conclusions: Baseline ﬁbulin-3 concentrations are associated with the incidence of clinical knee OA
among middle-aged overweight and obese women. Therewith, they meet the criteria of a prognostic
biomarker according to the BIPED biomarker classiﬁcation for OA. Further validation of the ﬁbulin-3
epitopes seems warranted in order to better distinguish subgroups of individuals at increased risk for
knee OA development.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a progressive disorder characterized by
synovial inﬂammation, bone remodeling, and degradation of the
extracellular matrix of articular cartilage1. Currently, the diagnosis
of OA is based on clinical and radiographic changes which occur late
in disease progression. This method does not allow early detection
of structural damage, and it is cumbersome to use in daily practice.to: Y. Henrotin, Bone and
y of Liege, CHU Sart-Tilman,
.
s.
ternational. Published by Elsevier LTherefore, there is an acute need for reliable biochemical markers
that can facilitate the diagnosis of OA and inform prognosis,
monitoring, and therapeutic strategies for the disease.
Biochemical markers of bone, synovium, or cartilage turnover
have been proposed as tools for the diagnosis and prognosis of OA
and for the monitoring of OA treatment2e4. However, at that time,
there were no reliable biomarkers for early diagnosis, for the
identiﬁcation of different OA phenotypes, or for use as surrogate
clinical end points5. Therefore, the discovery of novel OA bio-
markers is essential for drug discovery and development, for early
diagnosis, and to facilitate individualized treatment to improve
clinical outcomes.
Originally discovered by proteomic to be increase in OA urine,
the ﬁbulin-3 epitopes (Fib3-1, Fib3-2 and Fib3-3) contain a speciﬁc
sequence of ﬁbulin-3, an extracellular glycoprotein widelytd. All rights reserved.
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bone, ligament and cartilage6. Fibulin-3 inhibits angiogenesis and
chondrocyte differentiation7. More precisely, the overexpression of
ﬁbulin-3 suppresses chondrocyte differentiation by inhibition of
cartilage nodes formation, proteoglycan production and aggrecan
gene expression. Further, the overexpression of ﬁbulin-3 selectively
maintains the expression of Sox-9 but suppresses the expression of
Sox-5 and Sox-6. Fibulin-3 also interacts with the tissue inhibitor of
metalloproteinases (TIMP)-3, which is a matrix bound inhibitor of
matrix metalloproteinases (MMPs)8. Fibulin-3 is known to be
cleaved by MMP-1, -2, -3, -7, -9 and -129.
Using immunoassays for Fib3-1 and Fib3-2, two speciﬁc amino
acid sequences of ﬁbulin-3, we demonstrated that their levels were
increased in the serum of patients with severe knee OA compare to
age-matched healthy subjects. Using the area under the receiver
operating characteristic curve (ROC) analysis, Fib3-1 and Fib3-2
levels discriminated well normal and OA populations10.
The aim of this study was to determine the association between
three ﬁbulin-3 circulating epitopes and incidence of radiographic
and clinical knee OA in middle-aged overweight and obese women,
free of radiologic and symptomatic knee OA at baseline, using the
PROOF cohort.
Methods
For this study, data of the PROOF study were used. This ran-
domized controlled trial investigated the effects of a diet and ex-
ercise program and of oral glucosamine sulphate (double-blind and
placebo-controlled) on incidence of knee OA, in a 22 factorial
design11,12. The PROOF study included middle-aged women (50e60
years) with a BMI 27.0 kg/m2, but free of clinical and radiographic
knee OA at baseline. Additional inclusion criteria were: mastering
Dutch language, free of major-comorbidities and inﬂammatory
rheumatic diseases, not under treatment for knee complaints, not
using walking aids or glucosamine sulphate, and free of contrain-
dications for MRI12. In short, at baseline semi-ﬂexed posterior-
anterior knee radiographs were taken according to the meta-
tarsophalangeal (MTP) protocol13 and scored using Kellgren &
Lawrence (K&L) criteria14. Minimal joint space width was
measured by visual reading for each tibiofemoral compartment15
and medial knee alignment angle was assessed for all knees16. All
subjects underwent a physical examination, including determina-
tion of body weight and body height to calculate and stratify BMI
(27 but <30 kg/m2 as overweight and 30 kg/m2 as obesity),
presence of Heberden's nodes, triceps skin fold (for calculation of
fat percentage17), and waist circumference. Non-fasted serum was
collected using a venepuncture and stored at 80C. A question-
nairewas ﬁlled in, containing questions on the number of dayswith
knee pain, physical activity level (SQUASH18), knee complaints, the
Knee Injury and Osteoarthritis Outcome Score (KOOS) score19,
menopausal status, ethnicity, and co-morbidities. Using these data,
mild symptomswere deﬁned as present when a conﬁrming answer
was given to the question ‘did you experience knee pain in the last
12months?’, chronic knee pain for an additional conﬁrming answer
to ‘was the knee pain present on the most days of the last month?’,
and WOMAC pain, function and stiffness were calculated on a
0e100 scale using the KOOS scores. After 30 months, radiography
measurements and the questionnaire were repeated.
Using the serum samples, total cholesterol, glycated hemoglobin
(HbA1c) and three ﬁbulin-3 peptides were determined. The
sequence of Fib3-1, Fib3-2 and Fib3-3 were 331TCQDINE-
CETTNECR345, 377CVCPVSNAMCR387 and 430SGNENGEFYLR440,
respectively. They were quantiﬁed in triplicate by speciﬁc
competitive Enzyme-Linked Immunosorbent Assays (ELISAs)
(Artialis SA, Liege, Belgium). The immunoassays for measuringFib3-1, Fib3-2 or Fib3-3 have been developed using polyclonal
antibodies (AS88, AS94 and poly33-11, respectively) which did not
recognize complete ﬁbulin-3 and did not cross-react between each
other. For Fib3-1 and Fib3-2, the coating and the competition were
made using a bovine serum albumin (BSA)-coupled Fib3-1 or Fib3-
2 peptide. For Fib3-3, a streptavidin followed by the biotinylated-
peptide coating was performed and the uncoupled Fib3-3 peptide
was used for the competition. The lower detection limit was
232 pM, 482 pM and 500 pM for Fib3-1, Fib3-2 and Fib3-3 assay,
respectively. The within-run (intra-assay) precisions and the
between-run (inter-assay) precision were below 11%. Linearity was
shown by diluting samples serially and comparing the observed
values with those expected10. Serum samples were twice-diluted in
a PBS BSA 0.2% tween-20 0.1% buffer, pH 7.2 for Fib3-1 and Fib3-2,
and six-diluted in NaCl 0.9% BSA 7% for Fib3-3.
The present study selected all subjects with baseline serum and
complete follow-up data available. Baseline concentrations of all
ﬁbulin-3 fragments were checked for normal-distribution. For each
fragment, the univariate association with age, BMI, menopausal
status, years since menopause, fat percentage, waist circumference,
total cholesterol, glycated hemoglobin (HbA1c), physical activity
level, ethnicity, presence of Heberden's nodes, K&L grade 1 vs 0,
varus alignment, history of knee injury, presence of mild symp-
toms, and the presence of OA in other joints was assessed. Factors
with a P-value <0.2 for their associationwith the ﬁbulin-3 fragment
were selected for a multivariable analysis, wherein those with a P-
value <0.05 were selected. Subsequently, the associations of the
each of the three baseline ﬁbulin-3 concentrations separately and
all three together with the incidence of knee OA was determined
using logistic regression. Stepwise adjustment was applied: no
adjustments in model 1; adjustment for baseline age and BMI in
model 2 additional adjustment for signiﬁcant factors from the
multivariable analysis and the randomization groups of the original
trial (since data originate from a clinical trial, but were used as
cohort data) in model 3. Several outcome measures were used for
the incidence of knee OA at follow-up: incidence of medial joint
space narrowing (JSN)1.0 mm, lateral JSN1.0mm and of K&L2
for incident radiographic knee OA and incidence of the
radiographic þ clinical ACR-criteria20 and of chronic pain as inci-
dent clinical knee OA. To enable interpretation of the regression
associations, Fibulin-3 peptides concentrations were standardized
into z-scores. A z-score indicates the number of standard deviations
(SDs) that the original value deviates from the population mean.
The serum Fib-3-1, Fib3-2 and Fib3-3 levels were logarithmically
transformed before standardized into z-scores. Results for the
regression analyses were also presented as odds ratios per
SD increase in log Fib-3 and their corresponding 95% conﬁdence
intervals. Statistical analyses were performed with SPSS 20.0
(Chicago, IL). A P-value <0.05 was deﬁned as statistically signiﬁcant
in all logistic regression analyses.
Results
Immunoassays validation
As previously published, the antisera AS88 and AS94 have a high
afﬁnity for Fib3-1 and Fib3-2. Antisera did not recognize complete
ﬁbulin-3 or BSA and did not cross-react between Fib3-1 and Fib3-
210. Poly33-11 is speciﬁc for the Fib3-3 epitope without binding
entire ﬁbulin-3, BSA or Fib3-2 (Fig. 1). Linearity was shown by
diluting serum samples serially and comparing the observed values
with the expected values. For Fib3-3 assay, a recovery rate of 89.6%
at 1:4,102.9% at 1:8,105.1% at 1:12 and 102.4% at 1:16was observed
(n ¼ 8 performed in triplicate) when sera were diluted in NaCl 0.9%
BSA 7%.
Fig. 1. Competitive inhibition of Poly-33-11 with the ﬁbulin 3 peptides Fib3-3 and
Fib3-2, complete ﬁbulin-3, and BSA. B/B0 is the ratio of coated antigen bound in the
presence of free antigen to coated antigen bound in the absence of free antigen.
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Out of all women included in the PROOF study with bilateral
K&L <2, 241 had complete follow-up data and a serum sample
available and were selected for the present study. Baseline char-
acteristics are given in Table I. Of all baseline factors presented in
Table I, only physical activity level was signiﬁcantly higher in those
selected for the present study compared to those excluded
(7097 ± 3798 vs 6246 ± 3335, P ¼ 0.04). Incidence of medial JSN
1.0 mm after 30 months was seen in 26 out of 241 women (11%),
while lateral JSN was seen in 21 women (9%). Incidence of K&L 2,
the ACR-criteria and chronic pain after 30 months occurred in 22
(9%), 20 (8%) and 27 women (11%), respectively.
All three ﬁbulin-3 concentrations showed a non-normal distri-
bution at baseline. Therefore, log-transformed and subsequently Z-Table I
Baseline characteristics of included subjects (N ¼ 241)
Mean ± SD or percentage
Age (yr) 55.9 ± 3.2
BMI (kg/m2) 31.7 ± 3.6
WOMAC pain (0e100) 6.1 ± 10.2
WOMAC function (0e100) 5.9 ± 9.7
WOMAC stiffness (0e100) 11.6 ± 17.4
Joint space width
Medial (mm) 4.87 ± 0.67




Unilateral and bilateral 15% and 13%
K&L 1 57%
Unilateral and bilateral 24% and 33%
Varus alignment 50%
Unilateral and bilateral 19% and 30%
History of knee injury 29%
Unilateral and bilateral 15% and 14%
Mild symptoms 41%
Unilateral and bilateral 24% and 17%
Total cholesterol (mmol/L) 6.1 ± 1.1
HbA1c (mmol/mol) 39.1 ± 7.1
Fat percentage (%) 42.9 ± 4.8
Waist circumference (cm) 105 ± 9
Physical activity (SQUASH score) 7097 ± 3798
Western ethnicity 96%
OA in other joints 23%
Serum Fib3-1 (nM) 13.6 ± 3.7
Serum Fib3-2 (nM) 19.7 ± 8.9
Serum Fib3-3 (nM) 9.5 ± 4.5transformed concentration levels were used throughout the
analyses.
Baseline Fib3-1 and Fib3-2 concentrations had only a borderline
signiﬁcant associations with Heberden's nodes (P ¼ 0.09) and total
cholesterol (P ¼ 0.06) respectively in the multivariable analysis.
Fib3-3 was signiﬁcantly associated to HbA1c (P ¼ 0.02) and
borderline signiﬁcant to ethnicity (P ¼ 0.05) in the multivariable
analysis. Hence, model 3 of the Fib3-3 analysis was additionally
adjusted for baseline HbA1c level. Log-transformed baseline
ﬁbulin-3 concentrations did not differ between overweight and
obese individuals (Fib3-1: 2.49 ± 0.01 vs 2.46 ± 0.01 [P ¼ 0.23],
Fib3-2: 2.49 ± 0.02 vs 2.48 ± 0.01 [P ¼ 0.62], Fib3-3: 0.97 ± 0.02 vs
0.92 ± 0.02 [P ¼ 0.06] for overweight and obese individuals,
respectively).
The associations between the baseline concentrations of the
three ﬁbulin-3 epitopes separately and the different incident knee
OA measures are presented in Table II and Fig. 2. None of the
ﬁbulin-3 epitopes were signiﬁcantly associated to the incidence of
any of the radiographic knee OA measures. Contrary, apart from
Fib3-2 and incident chronic pain, all ﬁbulin-3 epitopes were
signiﬁcantly associated to both clinical knee OA measures in the
totally adjusted models. Model 3 showed no signiﬁcant effects for
adjustments for randomized intervention groups of the original
trial (data not shown). When the analyses were adjusted for each of
the baseline ﬁbulin-3 concentrations, only Fib3-1 was signiﬁcantly
associated to incidence of the ACR-criteria (OR 3.21 95% CI
1.19e8.70 inmodel 3) and chronic pain (OR 3.05 95% CI 1.20e7.71 in
model 3). Baseline concentrations of all three epitopes for subjects
with (I) and without incidence (NI) ACR-criteria and for chronic
pain at follow-up are presented in Fig. 3. The subjects with ACR-
criteria incidence had a signiﬁcant higher Fib3-1 (NI 13.5 ± 3.7 nM
vs I 16.1 ± 3.7 nM; P ¼ 0.007), Fib3-2 (NI 18.9 ± 6.8 nM vs I
24.1 ± 15.6 nM; P ¼ 0.0235) and Fib3-3 (9.4 ± 4.5 nM vs
11.5 ± 4.4 nM; P ¼ 0.0290) epitope concentrations at baseline than
subjects with non-incidence. Those with a chronic pain incidence
had signiﬁcant higher Fib3-1 (NI 13.5 ± 3.5 nM vs I 16.2 ± 4.8 nM;
P ¼ 0.008), but not Fib3-2 or Fib3-3, serum levels than those with
no chronic pain incidence.
Next, Fig. 4 presents the course of the epitope's concentrations
over the 30 months follow-up period for subjects with and without
incidence ACR-criteria and chronic pain at follow-up. No signiﬁcant
change of Fibulin-3 epitopes over 30 months was observed; Fib3-
1: 0.90 ± 4.25 nM vs 2.51 ± 3.61 nM (P ¼ 0.19), Fib3-
2: 0.42 ± 6.45 nM vs 1.87 ± 7.754 nM (P ¼ 0.35), Fib3-
3: 1.4 ± 3.8 nM vs 2.7 ± 3.8 nM (P ¼ 0.19) for NI and I of ACR-
criteria, respectively. For non-incidence and incidence of chronic
pain, epitope concentrations were: Fib3-1: 0.91 ± 4.37 nM
vs 2.17 ± 3.33 nM (P ¼ 0.27), Fib3-2: 0.42 ± 6.55 nM
vs 1.92 ± 5.05 nM (P ¼ 0.20), Fib3-3: 1.5 ± 3.8 nM
vs 1.9 ± 3.9 nM (P ¼ 0.62), respectively.Discussion
We have designed three immunoassays to quantify speciﬁc
epitopes of ﬁbulin-3 in serum. As our antibodies fail to recognize
the native ﬁbulin-3, we anticipate that these epitopes are located in
circulating fragments. Previously, we showed that Fib3-1 and Fib3-
2 were not correlated and probably reﬂected different biologic
processes. Fib3-1 was associated with aging and hormonal status,
while Fib3-2 was not modiﬁed by sex, age, or menopause10. Im-
munostaining, revealed the presence of Fib3-1 and Fib3-2 in
chondrocytes and in the extracellular matrix of the superﬁcial layer
of ﬁbrillated cartilage, but were absent in the surrounding unﬁ-
brillated zone. Finally, Fib3-1 and Fib3-2 discriminated well
Table II
Associations (odd ratios with 95% CI) of three ﬁbulin-3 fragments and incident knee OA measures at 30 months
Incidence Model 1* Model 2y Model 3z
Medial JSN 11%
Fib3-1 1.06 (0.61e1.84) 1.08 (0.61e1.91) 1.06 (0.59e1.91)
Fib3-2 0.66 (0.38e1.12) 0.65 (0.37e1.12) 0.65 (0.38e1.12)
Fib3-3 0.89 (0.57e1.37) 0.88 (0.56e1.36) 0.83 (0.53e1.32)
Lateral JSN 9%
Fib3-1 0.76 (0.41e1.43) 0.71 (0.38e1.35) 0.65 (0.32e1.31)
Fib3-2 0.88 (0.50e1.53) 0.87 (0.49e1.52) 0.89 (0.50e1.58)
Fib3-3 0.98 (0.61e1.57) 0.98 (0.61e1.58) 0.90 (0.54e1.50)
K&L ≥2 9%
Fib3-1 1.17 (0.68e2.04) 1.27 (0.70e2.30) 1.35 (0.73e2.51)
Fib3-2 1.17 (0.73e1.87) 1.16 (0.74e1.84) 1.20 (0.75e1.92)
Fib3-3 1.12 (0.70e1.78) 1.09 (0.68e1.75) 1.21 (0.73e2.00)
ACR-criteria 8%
Fib3-1 2.33 (1.26e4.34) 2.29 (1.21e4.35) 2.70 (1.26e5.75)
Fib3-2 1.67 (1.07e2.62) 1.68 (1.07e2.65) 1.72 (1.07e2.78)
Fib3-3 1.69 (1.01e2.82) 1.70 (1.01e2.84) 2.00 (1.10e3.65)
Chronic pain 11%
Fib3-1 2.26 (1.28e3.99) 2.41 (1.31e4.42) 2.62 (1.31e5.23)
Fib3-2 1.39 (0.92e2.09) 1.39 (0.92e2.08) 1.45 (0.95e2.22)
Fib3-3 1.43 (0.91e2.23) 1.44 (0.92e2.26) 1.72 (1.01e2.91)
Bold ﬁgures represent statistically signiﬁcant odd ratio's.
* Unadjusted.
y Adjusted for age and BMI.
z Additionally adjusted for signiﬁcant factors of multivariable analyses and randomized groups of the original study.
Fig. 2. Odds ratio's and 95% conﬁdence intervals for all three ﬁbulin-3 epitopes and the selected outcome measures.
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Until now, Fib3-3 was not investigated in animal model or human
cohort.
In this study, baseline ﬁbulin-3 epitope concentrations are
associated to the incidence of knee OA deﬁned by the radiological
and clinical ACR-criteria among middle-aged overweight and
obese women. In contrast, ﬁbulin-3 epitopes are not associated
with the knee JSN or the K&L score individually. Interestingly,
Fib3-1 epitope was also related to chronic pain suggesting a
relationship between ﬁbulin-3 epitopes and pain in OA patient.
This means that ﬁbulin-3 epitopes predict more clinical than
radiologic features in this population. We have then tried to ﬁnd in
the literature a rationale for this association, but ﬁbulin-3 remains
unexplored in OA. Therefore, our interpretation is speculative and
based on observation in other disease conditions. Fibulin-3 is
considered as a key elastogenic protein which control the growth
of elastic ﬁbers in ligament. In particular, with other ﬁbulins,ﬁbulin-3 binds the monomeric form of elastin (tropoelastin)
in vitro and is shown to be involved in various aspects of elastic
ﬁber development in vivo21. In OA joint, ligament laxity is
commonly observed, in early-stage OA, leading to joint instability
and then increased strain on joint tissue22. It's a major risk factor
in the development of OA23. Joint instability is a determinant of
pain in OA24,25. Therefore, we can emphasize that a degradation of
ﬁbulin-3 is associated with ligament hyperlaxity, joint instability,
and subsequently with pain.
Therewith, ﬁbulin-3 epitopes meet the criteria of a prognostic
biomarker according to the BIPED biomarker classiﬁcation for OA26.
Further validation of the ﬁbulin-3 fragments seems warranted in
order to better distinguish subgroups of individuals at increased
risk for knee OA development. Of course, a better characterization
of the circulating fragments are necessary to better understand
ﬁbulin-3 metabolism in healthy and OA conditions, but also to
better interpret the data provided by the immunoassays.
Fig. 3. Mean of log- and Z-transformed baseline concentrations for subjects with and without incidence of ACR-criteria (upper row) and chronic pain at follow-up (lower row) for
ﬁb3-1 (panels A and D), ﬁb3-2 (panels B and E) and ﬁb3-3 (panels C and F). Statistical signiﬁcance between incidence or no incidence with ManneWhitney test.
Fig. 4. Mean baseline and 30 months follow-up concentrations with 95% conﬁdence intervals of ﬁb3-1 (in nM, panels A and D), ﬁb3-2 (in nM, panels B and E) and ﬁb3-3 (in nM,
panels C and F) for subjects with and without incidence of ACR-criteria (upper row) and chronic pain at follow-up (lower row). Asterisks mark statistical signiﬁcance for un-
transformed baseline concentrations between incidence or no incidence with ManneWhitney test (P < 0.05).
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mation about the size and the form of the circulating ﬁbulin-3
epitopes. Further, we lack information about the role played by
ﬁbulin-3 in OA, making the data interpretation speculative. Fibulin-3 is a ubiquitous protein suggesting that peptides released in the
blood stream probably come from different tissues. The tissue
speciﬁcity of an epitope is not required by OARSI to classify a
biomarker in the prognostic biomarkers category. Therefore,
J. Runhaar et al. / Osteoarthritis and Cartilage 24 (2016) 672e678 677despite this lack of speciﬁcity, Fib-3 fragment can be considered as
potential prognostic biomarkers. However, we recognize that this
lack of tissue speciﬁcity could be a major concern to predict disease
incidence or progression in a general population developing
concomitant diseases. In this study, patients have been selected on
the basis of strict criteria, excluding patients with severe vascular
diseases and major co-morbidities. Further, Fib-3 peptides did not
differ between overweight and obese individuals and are not
correlated with the BMI, suggesting that they are not linked to co-
morbidity like an increased adiposity in these subjects Therefore,
we can considered that Fib fragments changes reﬂect OA disease
condition. One other limitation of this study is that it was per-
formed using samples from overweight and obese women, who are
not representative of the general OA population. It is difﬁcult to
extrapolate the predictive value of ﬁbulin-3 epitopes to other OA
subphenotypes. Further studies investigating the relationship be-
tween OA incidence and progression and the level of ﬁbulin-3
epitopes are required to qualify these biomarkers as prognosis
biomarkers in general population. Finally, the incidence of OA is
low, but common, in this cohort. This means that the number of
subjects who developed OA represented a small sample, limiting
the power of the statistical analysis. The follow-up of this cohort
will allow to increase OA population and perhaps, to conﬁrm these
ﬁndings.
In this study of overweight and obese middle-aged women at
risk for developing knee OA, high serum Fib3-1, Fib3-2 and Fib3-3
levels were signiﬁcantly associated with increased risk of inci-
dence of symptomatic knee OA 2.5 years later. It is in the early pre-
clinical phase that distinguishing subjects who are at risk to
develop symptomatic knee OA from those who are not, has the
highest priority.
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